Literature DB >> 11221836

Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.

C F Hung1, K F Hsu, W F Cheng, C Y Chai, L He, M Ling, T C Wu.   

Abstract

Recently, Flt3 (Fms-like tyrosine kinase 3)-ligand has been identified as an important cytokine for the generation of professional antigen-presenting cells (APCs), particularly dendritic cells (DCs). A recombinant chimera of the extracellular domain of Flt3-ligand (FL) linked to a model antigen may potentially target the antigen to DCs and their precursor cells. Using human papillomavirus-16 E7 as a model antigen, we evaluated the effect of linkage to FL on the potency of antigen-specific immunity generated by naked DNA vaccines administered intradermally via gene gun. We found that vaccines containing chimeric FL-E7 fusion genes significantly increased the frequency of E7-specific CD8+ T cells relative to vaccines containing the wild-type E7 gene. In vitro studies indicated that cells transfected with FL-E7 DNA presented E7 antigen through the MHC class I pathway more efficiently than wild-type E7 DNA. Furthermore, bone marrow-derived DCs pulsed with cell lysates containing FL-E7 fusion protein presented E7 antigen through the MHC class I pathway more efficiently than DCs pulsed with cell lysates containing wild-type E7 protein. More importantly, this fusion converted a less effective vaccine into one with significant potency against established E7-expressing metastatic tumors. The FL-E7 fusion vaccine mainly targeted CD8+ T cells, and antitumor effects were completely CD4 independent. These results indicate that fusion of a gene encoding the extracellular domain of FL to an antigen gene may greatly enhance the potency of DNA vaccines via CD8-dependent pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221836

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  Targeting vaccines to dendritic cells.

Authors:  Camilla Foged; Anne Sundblad; Lars Hovgaard
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

Review 2.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

3.  The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.

Authors:  Emeline Ragonnaud; Peter Holst
Journal:  Ther Adv Vaccines       Date:  2013-05

Review 4.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

5.  Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.

Authors:  P P Ip; A Boerma; M Walczak; K Oosterhuis; J B Haanen; T N Schumacher; H W Nijman; T Daemen
Journal:  Gene Ther       Date:  2015-03-26       Impact factor: 5.250

Review 6.  Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Authors:  Chien-Fu Hung; Barbara Ma; Archana Monie; Shaw-Wei Tsen; T-C Wu
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

Review 7.  DNA vaccines for cervical cancer: from bench to bedside.

Authors:  Chien-Fu Hung; Archana Monie; Ronald D Alvarez; T-C Wu
Journal:  Exp Mol Med       Date:  2007-12-31       Impact factor: 8.718

8.  DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity.

Authors:  Cheng-Tao Lin; Ya-Chea Tsai; Liangmei He; Chun-Nan Yeh; Ting-Chang Chang; Yung-Kuei Soong; Archana Monie; Chien-Fu Hung; Chyong-Huey Lai
Journal:  Immunol Lett       Date:  2007-10-16       Impact factor: 3.685

9.  Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.

Authors:  James A Triccas; Elena Shklovskaya; Joanne Spratt; Anthony A Ryan; Umaimainthan Palendira; Barbara Fazekas de St Groth; Warwick J Britton
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

Review 10.  Antigen-specific immunotherapy of cervical and ovarian cancer.

Authors:  Chien-Fu Hung; T C Wu; Archana Monie; Richard Roden
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.